A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer.
- Author:
Kwang Sun LEE
1
;
Ha Yeon LEE
;
Eun Kyung PARK
;
Joung Soon JANG
;
Sang Jae LEE
Author Information
1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. sangjael@cau.ac.kr
- Publication Type:Original Article
- Keywords:
Docetaxel;
Fluorouracil;
Stomach neoplasms
- MeSH:
Alopecia;
Anemia;
Disease-Free Survival;
Drug Therapy, Combination;
Fever;
Fluorouracil;
Humans;
Leucovorin;
Neutropenia;
Stomach Neoplasms;
Taxoids
- From:Cancer Research and Treatment
2008;40(1):11-15
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer. MATERIALS AND METHODS: Total 27 patients are enrolled in this study. LV 20 mg/m2 (bolus), 5FU 400 mg/m2 (bolus), 5-FU 600 mg/m2 (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m2 (1-hour infusion) on day 15 every 4 weeks. RESULTS: Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0~12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0~8.5) and the median overall survival time is 11.9 months (95% CI, 4.8~19.1). The grade 3-4 toxcity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxcity of injection site reaction is observed all patients and the grade 1-2 toxcity of alopecia is observed 60%. CONCLUSIONS: LV5FU2 with docetaxel combination chemotheraphy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.
